Health Care [ 6/12 ] | Biotechnology [ 45/74 ]
NASDAQ | Common Stock
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota.
Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 8, 23 | -1.51 Decreased by -77.09% | - |
Aug 10, 23 | -3.24 Decreased by -575.00% | -4.50 Increased by +28.00% |
May 10, 23 | -0.38 Increased by +26.92% | -0.09 Decreased by -322.22% |
Mar 23, 23 | -0.56 Decreased by -40.00% | -0.34 Decreased by -64.71% |
Nov 10, 22 | -0.85 Decreased by -304.76% | -0.40 Decreased by -112.50% |
Aug 11, 22 | -0.48 Decreased by -50.00% | -0.41 Decreased by -17.07% |
May 16, 22 | -0.52 Increased by +48.00% | - |
Mar 31, 22 | -0.40 Decreased by -42.86% | -0.32 Decreased by -25.00% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 23 | 0.00 Decreased by -100.00% | -2.42 M Increased by +93.98% | Decreased by N/A% Decreased by N/A% |
Jun 30, 23 | 0.00 Decreased by -100.00% | -6.95 M Increased by +69.48% | Decreased by N/A% Decreased by N/A% |
Mar 31, 23 | 107.00 K Decreased by -69.77% | -63.94 M Decreased by -160.40% | Decreased by -59.76 K% Decreased by -761.52% |
Dec 31, 22 | 8.00 K Decreased by -99.01% | -26.32 M Decreased by -38.14% | Decreased by -329.02 K% Decreased by -13.82 K% |
Sep 30, 22 | 138.00 K Decreased by -98.78% | -40.11 M Decreased by -302.91% | Decreased by -29.07 K% Decreased by -33.02 K% |
Jun 30, 22 | 361.00 K Decreased by -87.24% | -22.77 M Decreased by -50.12% | Decreased by -6.31 K% Decreased by -1.08 K% |
Mar 31, 22 | 354.00 K Decreased by -90.04% | -24.55 M Decreased by -75.62% | Decreased by -6.94 K% Decreased by -1.66 K% |
Dec 31, 21 | 806.00 K Decreased by -55.40% | -19.05 M Decreased by -45.56% | Decreased by -2.36 K% Decreased by -226.33% |